Takeda Pharmaceutical Company Limited

Masakuni Kori

Shinji Nakamura

Toshihiro Imaeda

Masashi Toyofuku

Eiji Honda

Osamu Ujikawa

Yasutomi Asano

Michiyo Mochizuki

Albert Charles Gyorkos

Takahiro Matsumoto

Christopher Peter Corrette

Kazuyoshi Aso

Suk Young Cho

Timothy Mark Turner

Steven Armen Boyd

Kevin Ronald Condroski

Norihito Tokunaga

Shoji Fukumoto

Satoshi Mikami

Shinji Morimoto

Koichiro Fukuda

Kouichi Iwanaga

Scott Alan Pratt

Christopher Stephen Siedem

Yoshihiro Kiyota

Kazumasa Hamamura

Mitsunori Kouno

Junichi Miyazaki

Michiyo Gyoten

Hiromitsu Fuse

Toshihiro Yamamoto

Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (&#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Heterocyclic compound and use thereof

Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification,or a salt thereof.

Sulfonamide derivative and use thereof

There is provided a CRF receptor antagonist comprising a compound of the formula (I):A-W&#x2014;Ar&#x2003;&#x2003;(I) 

Cyclic compounds

There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I): wherein Z is oxygen or sulfur; Ris aryl which may be substituted, or a heterocyclic group which may be substituted; Ris a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; Ris piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; Ris a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, &#x2014;CO&#x2014;, etc.; and Ris a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

Amide compound

A compound represented by the formula (I) or a salt thereof; and an agent for protecting a brain/neuronal cell or a therapeutic agent for sleep disorder comprising the compound or salt: wherein Z represents an oxygen or sulfur; Rrepresents an aryl or heterocyclic group which may be substituted, provided that Ris not a 3-ethyl-6-methoxy-2-methyl-5-naphthalen-1-yl group; Rrepresents a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxyl group or the like; Rrepresents a piperidin-1,4-diyl or piperazin-1,4-diyl which may be substituted; Rrepresents a bivalent group which is formed by removing two hydrogen atoms from a benzene ring or 6-membered aromatic heterocyclic ring which may have a substituent, provided that Ris not a pyridazin-3,6-diyl; and Rrepresents a group which is formed by removing one hydrogen atom from a benzene ring or 5- to 6-membered heterocyclic ring which may be substituted, provided that the substituent on the heterocyclic ring is not a phenylethyl group which may be substituted when Z is sulfur. 

Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder

There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A'): wherein X is a carbon and Xis an oxygen, a sulfur or &#x2014;NR&#x2014;, or formula (A&#x2033;): wherein X is a nitrogen and Ris an optionally substituted hydrocarbyl, Ris an amino substituted by two optionally substituted hydrocarbyl groups, Ris an phenyl, Yis CRor a nitrogen, Yis CRor a nitrogen and Yis CRor a nitrogen, provided that one or less of Y, Y, and Yis nitrogen, W is a bond, &#x2014;(CH)n-, and Z is a bond, &#x2014;NR&#x2014;, etc.; or a salt thereof or a prodrug thereof.

Nitrogen-containing fused heterocyclic compounds

The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formulawherein Aris an aromatic ring group optionally having substituents, Aris an aromatic ring group having substituents, OR&#x2033; is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

Aminoethanol derivatives

Growing community of inventors

Osaka, Japan

Masakuni Kori